ResearchRapid Clonal Selection Within Early Hematopoietic Cell Compartments Presages the Outcome of Ivosidenib Combination Therapy
ResearchRisk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
ResearchTreatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy
ResearchGenetic and Phenotypic Correlates of Clinical Outcomes With Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
ResearchAzacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
ResearchMultimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States
ResearchIvosidenib or Venetoclax Combined With Hypomethylating Agents in IDH1-Mutated Acute Myeloid Leukemia: A Real-World Study
ResearchThromboprophylaxis With Intermediate Dose Enoxaparin During Asparaginase Containing Induction for Young Adults With Acute Lymphoblastic Leukemia
ResearchRefined ELN 2024 Risk Stratification Improves Survival Prognostication Following Venetoclax-Based Therapy in AML